Functional genomics: paving the way for more successful cancer immunotherapy

被引：6
|
作者：
Ajina, Reham [1 ]
Zamalin, Danielle [2 ]
Weiner, Louis M. [3 ,4 ,5 ]
机构：
[1] Georgetown Univ, Tumor Biol, Washington, DC 20057 USA
[2] Georgetown Univ, Washington, DC 20057 USA
[3] Georgetown Univ, Georgetown Lombardi Comprehens Canc Ctr LCCC, Washington, DC 20057 USA
[4] Dept Oncol, Washington, DC USA
[5] MedStar Georgetown Canc Inst, Washington, DC USA
来源：
BRIEFINGS IN FUNCTIONAL GENOMICS | 2019年 / 18卷 / 02期
关键词：
cancer; functional genomics; immunotherapy; checkpoints; immunity; T-CELL-RECEPTOR; CLONAL EXPANSION; PD-L1; EXPRESSION; OPEN-LABEL; TUMOR; IPILIMUMAB; RESISTANCE; MECHANISMS; BLOCKADE; PEMBROLIZUMAB;
D O I：
10.1093/bfgp/ely017
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Immunotherapies have revolutionized cancer treatment. Immunotherapy is effective for the treatment of a wide range of cancer types and can mediate complete and durable tumor regression. Nonetheless, the field still faces many significant challenges, such as the need for personalized therapeutic strategies and better biomarkers, the difficulty of selecting the right combination therapy, and resistance to currently available immunotherapies. Both cancer and host immunity comprise significantly diverse and complex ecosystems, making immunogenomics an ideal field for functional genomics analysis. In this review, we describe the cancer-immunity cycle, how cancer cells manage to evade immune attack and the current hurdles in the path of cancer immunotherapy. Then, we discuss how functional genomics approaches can pave the way for more successful cancer immunotherapies.
引用
收藏
页码：86 / 98
页数：13
相关论文
共 50 条
  • [1] Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy
    Yuan, Megan
    Wang, Wenjun
    Hawes, Isobel
    Han, Junwen
    Yao, Zhenyu
    Bertaina, Alice
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] Considerations for successful cancer immunotherapy in aged hosts
    Hurez, Vincent
    Padron, Alvaro
    Svatek, Robert S.
    Curiel, Tyler J.
    EXPERIMENTAL GERONTOLOGY, 2018, 107 : 27 - 36
  • [3] Considerations for successful cancer immunotherapy in aged hosts
    Hurez, V.
    Padron, A. S.
    Svatek, R. S.
    Curiel, T. J.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2017, 187 (01): : 53 - 63
  • [4] Immunotherapy in Breast Cancer-Paving New Roads?
    Truica, Cristina I.
    Cleary, Allison S.
    CURRENT MOLECULAR PHARMACOLOGY, 2016, 9 (03) : 208 - 216
  • [5] A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way
    Balar, Pankti C.
    Apostolopoulos, Vasso
    Chavda, Vivek P.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 969
  • [6] Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward
    Koedijk, Joost B.
    van der Werf, Inge
    Calkoen, Friso G.
    Nierkens, Stefan
    Kaspers, Gertjan J. L.
    Zwaan, Christian Michel
    Heidenreich, Olaf
    CANCERS, 2021, 13 (17)
  • [7] Genomics-Guided Immunotherapy for Precision Medicine in Cancer
    Mukherjee, Shradha
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2019, 34 (08) : 487 - 497
  • [8] The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer
    Jansen, Caroline S.
    Prokhnevska, Nataliya
    Kissick, Haydn T.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (08) : 543 - 555
  • [9] Immunotherapy for prostate cancer : Requirements for a successful regime transfer
    Jeong, Seung-Hwan
    Kwak, Cheol
    INVESTIGATIVE AND CLINICAL UROLOGY, 2022, 63 (01) : 3 - 13
  • [10] Paving the way for targeting RSK in cancer
    Romeo, Yves
    Roux, Philippe P.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (01) : 5 - 9
12345